Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer-Reference-Cited by-同舟云学术

Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer

Published:2006-06-27 Issue:10 Volume:14 Page:1030-1037
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Fagnoni Philippe,Limat Samuel,Chaigneau Loïc,Guardiola Emmanuel,Briaud Stéphanie,Schmitt Bernard,Merrouche Yacine,Pivot Xavier,Woronoff-Lemsi Marie-Christine

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-006-0062-5.pdf

Reference29 articles.

1. Abels R (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A:S2–S8

2. Baltussen R, Leidl R, Ament A (1999) Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making. PharmacoEconomics 16:449–458

3. Barosi G, Marchetti M, Liberato NL (1998) Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 78:781–787

4. Berndt E, Crown W, Kallich J, Long S, Song X, Lyman GH (2005) The impact of anaemia and its treatment on employee disability and medical costs. PharmacoEconomics 23:183–192

5. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201–2216

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria;Supportive Care in Cancer;2017-02-15

2. Cost–utility analyses of drug therapies in breast cancer: a systematic review;Breast Cancer Research and Treatment;2016-08-30

3. Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment;Clinical and Applied Thrombosis/Hemostasis;2016-07-20

4. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model;Health Technology Assessment;2016-02

5. Erythropoietin or darbepoetin for patients with cancer;Cochrane Database of Systematic Reviews;2012-12-12